{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:40:22Z","timestamp":1773798022347,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.juro.2017.04.102","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T16:02:06Z","timestamp":1494086526000},"page":"817-823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications"],"prefix":"10.1097","volume":"198","author":[{"given":"Stephanie A.M.","family":"Wankowicz","sequence":"first","affiliation":[{"name":"Bladder Cancer Center, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Cancer Center, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Cancer Center, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Orsola","sequence":"additional","affiliation":[{"name":"Bladder Cancer Center, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Cancer Center, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Novak","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Cancer Center, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Bowden","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Cancer Center, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Bladder Cancer Center, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"de Torres","sequence":"additional","affiliation":[{"name":"Department of Pathology, Vall d'Hebron Hospital, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Morote","sequence":"additional","affiliation":[{"name":"Department of Urology, Vall d'Hebron Hospital, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon J.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[{"name":"Bladder Cancer Center, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Cancer Center, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2017.04.102_bib1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.juro.2017.04.102_bib2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.04.102_bib3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.urology.2006.03.062","article-title":"Clinical model of lifetime cost of treating bladder cancer and associated complications","volume":"68","author":"Avritscher","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.juro.2017.04.102_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1200\/JCO.2014.57.6967","article-title":"Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients","volume":"33","author":"Martin-Doyle","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.04.102_bib5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2017.04.102_bib6","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.4049\/jimmunol.160.12.6188","article-title":"An antigen recognized by autologous CTLs on a human bladder carcinoma","volume":"160","author":"Gu\u00e9guen","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.juro.2017.04.102_bib7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2017.04.102_bib8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.juro.2017.04.102_bib9","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.juro.2017.04.102_bib10","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2017.04.102_bib11","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J Immunol"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.04.102_bib12","article-title":"Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012","volume":"33","author":"Plimack","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.04.102_bib13","article-title":"IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC)","volume":"34","author":"Hoffman-Censits","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.04.102_bib14","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/bjc.2014.633","article-title":"Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients","volume":"112","author":"Orsola","year":"2015","journal-title":"Br J\u00a0Cancer"},{"key":"10.1016\/j.juro.2017.04.102_bib15","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","article-title":"Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers","volume":"56","author":"Nakanishi","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.juro.2017.04.102_bib16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdv009","article-title":"Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma","volume":"26","author":"Bellmunt","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.juro.2017.04.102_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/cmi.2010.28","article-title":"Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer","volume":"7","author":"Zhang","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.juro.2017.04.102_bib18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ijc.25397","article-title":"PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients","volume":"128","author":"Shi","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.juro.2017.04.102_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.juro.2017.04.102_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejso.2013.08.023","article-title":"Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder","volume":"40","author":"Xylinas","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.juro.2017.04.102_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.juro.2017.04.102_bib22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1074-7613(04)00050-0","article-title":"B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes","volume":"20","author":"Dong","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.juro.2017.04.102_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.imlet.2004.05.007","article-title":"The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role","volume":"94","author":"Youngnak-Piboonratanakit","year":"2004","journal-title":"Immunol Lett"},{"key":"10.1016\/j.juro.2017.04.102_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.juro.2017.04.102_bib25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/2326-6066.CIR-15-0024","article-title":"Long-term benefit of PD-L1 blockade in lung cancer associated with JAK3 activation","volume":"3","author":"Van Allen","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.juro.2017.04.102_bib26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1541-7786.MCR-12-0274","article-title":"Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma","volume":"10","author":"van der Horst","year":"2012","journal-title":"Mol Cancer Res"},{"issue":"suppl.","key":"10.1016\/j.juro.2017.04.102_bib27","article-title":"Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced\/metastatic urothelial carcinoma (mUC): primary analysis of IMvigor210 cohort 1","volume":"34","author":"Balar","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2017.04.102_bib28","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.juro.2017.04.102_bib29","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717646846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534717646846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2017.04.102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T23:52:42Z","timestamp":1719186762000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2017.04.102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1016\/j.juro.2017.04.102"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2017.04.102","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2017.04.102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}